UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Though the connection seems unusual, this news could change the lives of more than 700,000 Americans living with this disease ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...

cretostimogene grenadenorepvec may be a much-needed advancement in the bladder cancer treatment paradigm that could help thousands of patients avoid surgery. Complete removal of the bladder is a ...

ImmunityBio is seeking an urgent meeting with U.S. health regulators after its bladder-cancer treatment application was rejected. The immunotherapy company said Monday that it received a ...

May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

Congressman Greg Murphy, M.D., is recognizing May as Bladder Cancer Awareness Month. “While most bladder cancers are caught ...